Verastem (VSTM) News Today $6.40 -0.17 (-2.59%) Closing price 04:00 PM EasternExtended Trading$6.42 +0.02 (+0.39%) As of 06:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Verastem (NASDAQ:VSTM) Upgraded to Hold at StockNews.comMarch 26 at 3:35 AM | americanbankingnews.comVerastem (NASDAQ:VSTM) Upgraded to "Hold" at StockNews.comStockNews.com raised Verastem from a "sell" rating to a "hold" rating in a research note on Monday.March 25 at 11:06 PM | marketbeat.comVerastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025March 25 at 4:35 PM | businesswire.comVerastem (NASDAQ:VSTM) Price Target Raised to $14.00Guggenheim increased their price objective on Verastem from $13.00 to $14.00 and gave the company a "buy" rating in a report on Monday.March 25 at 9:42 AM | marketbeat.comVerastem (NASDAQ:VSTM) Given New $10.00 Price Target at HC WainwrightHC Wainwright raised their price target on shares of Verastem from $7.00 to $10.00 and gave the stock a "buy" rating in a research report on Monday.March 25 at 8:12 AM | marketbeat.comGuggenheim Forecasts Strong Price Appreciation for Verastem (NASDAQ:VSTM) StockMarch 25 at 2:52 AM | americanbankingnews.comVerastem price target raised to $14 from $13 at GuggenheimMarch 24 at 7:04 PM | markets.businessinsider.comVerastem CFO Daniel Calkins sells shares worth $630March 24 at 4:41 PM | investing.comVerastem price target raised to $10 from $7 at H.C. WainwrightMarch 24 at 2:03 PM | markets.businessinsider.comVerastem’s Promising Financial Outlook and Strategic Advancements Drive Buy RatingMarch 24 at 6:29 AM | tipranks.comRoyal Bank of Canada Cuts Verastem (NASDAQ:VSTM) Price Target to $14.00March 24 at 1:49 AM | americanbankingnews.comRosalind Advisors Inc. Takes Position in Verastem, Inc. (NASDAQ:VSTM)Rosalind Advisors Inc. purchased a new stake in Verastem, Inc. (NASDAQ:VSTM - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 900,000 shares of the biopharmaceutical company's stock, valued at approximatMarch 23 at 5:49 AM | marketbeat.comAlliance Global Partners Remains a Buy on Verastem (VSTM)March 22, 2025 | markets.businessinsider.comRoyal Bank of Canada Has Lowered Expectations for Verastem (NASDAQ:VSTM) Stock PriceRoyal Bank of Canada dropped their price target on shares of Verastem from $16.00 to $14.00 and set an "outperform" rating for the company in a research note on Friday.March 22, 2025 | marketbeat.comBTIG Sticks to Its Buy Rating for Verastem (VSTM)March 21, 2025 | markets.businessinsider.comVerastem price target lowered to $14 from $16 at RBC CapitalMarch 21, 2025 | markets.businessinsider.comVerastem (NASDAQ:VSTM) Issues Quarterly Earnings ResultsVerastem (NASDAQ:VSTM - Get Free Report) posted its quarterly earnings results on Thursday. The biopharmaceutical company reported ($1.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.57).March 21, 2025 | marketbeat.comVerastem (NASDAQ:VSTM) Announces Quarterly Earnings ResultsVerastem (NASDAQ:VSTM - Get Free Report) issued its quarterly earnings data on Thursday. The biopharmaceutical company reported ($1.33) earnings per share for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.57).March 21, 2025 | marketbeat.comVerastem reports Q4 EPS (60c), consensus (74c)March 21, 2025 | markets.businessinsider.comVerastem files to sell 1.42M shares of common stock for holdersMarch 21, 2025 | markets.businessinsider.comVerastem Unveils Strategic Plans in New PresentationMarch 20, 2025 | tipranks.comVerastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights ...March 20, 2025 | gurufocus.comVerastem, Inc. (NASDAQ:VSTM) Receives Consensus Recommendation of "Buy" from BrokeragesMarch 20, 2025 | americanbankingnews.comVerastem, Inc. (NASDAQ:VSTM) Receives Consensus Rating of "Buy" from BrokeragesShares of Verastem, Inc. (NASDAQ:VSTM - Get Free Report) have been assigned an average recommendation of "Buy" from the nine ratings firms that are currently covering the company, Marketbeat reports. Nine analysts have rated the stock with a buy rating. The average 12 month target price among brokMarch 20, 2025 | marketbeat.comVerastem CEO sells shares worth $1,695March 19, 2025 | investing.comVerastem (NASDAQ:VSTM) Share Price Passes Above 200 Day Moving Average - Here's What HappenedMarch 19, 2025 | americanbankingnews.comVerastem (NASDAQ:VSTM) Stock Passes Above 200-Day Moving Average - Here's WhyVerastem (NASDAQ:VSTM) Stock Crosses Above Two Hundred Day Moving Average - What's Next?March 19, 2025 | marketbeat.comVerastem: Upcoming PDUFA, But I Remain CautiousMarch 11, 2025 | seekingalpha.comVerastem (VSTM) to Release Quarterly Earnings on ThursdayVerastem (NASDAQ:VSTM) will be releasing earnings before the market opens on Thursday, March 13, Financial Modeling Prep reports.March 11, 2025 | marketbeat.comVerastem (VSTM) Expected to Announce Earnings on ThursdayVerastem (NASDAQ:VSTM) will be releasing earnings before the market opens on Thursday, March 13, Financial Modeling Prep reports.March 6, 2025 | marketbeat.comVerastem (NASDAQ:VSTM) Stock Price Passes Above 200 Day Moving Average - Should You Sell?Verastem (NASDAQ:VSTM) Share Price Passes Above 200 Day Moving Average - Should You Sell?March 4, 2025 | marketbeat.comVerastem, Inc. (NASDAQ:VSTM) Given Consensus Rating of "Buy" by BrokeragesVerastem, Inc. (NASDAQ:VSTM - Get Free Report) has been given a consensus recommendation of "Buy" by the nine brokerages that are currently covering the firm, MarketBeat Ratings reports. Nine equities research analysts have rated the stock with a buy rating. The average 12 month price objective amFebruary 23, 2025 | marketbeat.comVerastem (NASDAQ:VSTM) Share Price Crosses Above 200-Day Moving Average - What's Next?Verastem (NASDAQ:VSTM) Stock Price Crosses Above Two Hundred Day Moving Average - Time to Sell?February 22, 2025 | marketbeat.comVerastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s CancerFebruary 21, 2025 | finance.yahoo.comAlyeska Investment Group Reduces Stake in Verastem IncFebruary 15, 2025 | gurufocus.comNantahala Capital Management, LLC Increases Stake in Verastem IncFebruary 15, 2025 | gurufocus.comVerastem CEO Dan Paterson sells shares worth $4,890February 5, 2025 | msn.comVerastem price target raised to $9 from $7 at B. RileyJanuary 31, 2025 | markets.businessinsider.comVanguard Group Inc. Increases Stake in Verastem Inc.January 31, 2025 | gurufocus.comB. Riley Issues Positive Forecast for Verastem (NASDAQ:VSTM) Stock PriceB. Riley raised their price objective on Verastem from $7.00 to $9.00 and gave the company a "buy" rating in a research note on Friday.January 31, 2025 | marketbeat.comShort Interest in Verastem, Inc. (NASDAQ:VSTM) Increases By 59.5%Verastem, Inc. (NASDAQ:VSTM - Get Free Report) saw a significant growth in short interest in the month of January. As of January 15th, there was short interest totalling 4,930,000 shares, a growth of 59.5% from the December 31st total of 3,090,000 shares. Approximately 12.5% of the shares of the company are short sold. Based on an average daily volume of 1,480,000 shares, the short-interest ratio is presently 3.3 days.January 31, 2025 | marketbeat.comVerastem Oncology to Present at the Guggenheim SMID Cap Biotech ConferenceJanuary 29, 2025 | businesswire.comMizuho Securities Sticks to Its Buy Rating for Verastem (VSTM)January 24, 2025 | markets.businessinsider.comMizuho maintains Verastem stock outperform with $9 targetJanuary 24, 2025 | msn.comVerastem (NASDAQ:VSTM) Earns "Buy" Rating from GuggenheimGuggenheim reissued a "buy" rating on shares of Verastem in a research report on Friday.January 24, 2025 | marketbeat.comRBC Capital reiterates Outperform after Verastem formalizes key 2025 prioritiesJanuary 24, 2025 | markets.businessinsider.comVerastem Inches up on ’25 LookaheadJanuary 23, 2025 | baystreet.caCantor Fitzgerald Forecasts Verastem FY2025 EarningsVerastem, Inc. (NASDAQ:VSTM - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Verastem in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos forecasts that the biopharmaceutical company wJanuary 23, 2025 | marketbeat.comVerastem Expands Oncology Pipeline with VS-7375 AcquisitionJanuary 23, 2025 | tipranks.comVerastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven CancersJanuary 23, 2025 | businesswire.com Remove Ads Get Verastem News Delivered to You Automatically Sign up to receive the latest news and ratings for VSTM and its competitors with MarketBeat's FREE daily newsletter. Email Address VSTM Media Mentions By Week VSTM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VSTM News Sentiment▼0.270.89▲Average Medical News Sentiment VSTM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VSTM Articles This Week▼304▲VSTM Articles Average Week Remove Ads Get Verastem News Delivered to You Automatically Sign up to receive the latest news and ratings for VSTM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies OPKO Health News Geron News Innoviva News Myriad Genetics News Rigel Pharmaceuticals News Emergent BioSolutions News Vanda Pharmaceuticals News Codexis News XOMA News Ironwood Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VSTM) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredHere’s Why Tesla Insiders are Dumping SharesTesla has been on a losing streak ever since Elon Musk first visited the White House in early 2025. Our res...Behind the Markets | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verastem, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verastem With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VSTM Stock Free VSTM Stock Alerts